Biotech Values

[hirogen]

For a while now they appear to have been looking for a way to get an orphan indication as the first indication. I would presume in order to take advantage of priming (setting the initial price very high).

It seems strange that since the 1Q call three months ago the Eyeguard A timeline slipped >6 months such that the BLA may be based only on the B trial. I don't think I agree with the orphan drug strategy, if this had any bearing on delays tacit or otherwise, with Adalimumab VISUAL trials underway.

Finally note that previously I commented on their late schedule pop for osteo. Apparently a pattern.

A good calibration point on their forthrightness and/or clinical operational management.